OTTAWA – As the federal government prepares the upcoming budget, Breast Cancer Canada (BCC) has issued a comprehensive and urgent written submission to the House of Commons Standing Committee on Finance. The submission outlines a strategic tripartite framework designed to modernize the nation’s approach to breast cancer—a disease that continues to claim over 5,500 Canadian lives annually, a figure that has remained tragically stagnant for two decades.
The submission serves as a clarion call for the Government of Canada to transition from a fragmented, province-by-province approach to a unified, national standard of care. By focusing on regulatory modernization, precision oncology, and the integration of artificial intelligence (AI) in patient data collection, BCC argues that Canada can not only improve survival rates but also bolster the national economy by reducing healthcare inefficiencies and helping patients return to the workforce sooner.
Main Facts: The Three Pillars of Reform
Breast Cancer Canada’s pre-budget submission is anchored by three primary recommendations, each addressing a specific systemic failure in the current healthcare landscape.
1. National Standardization of Care
BCC is calling on the Public Health Agency of Canada (PHAC) to formally recognize and support the implementation of the REAL Canadian Breast Cancer Alliance evidence-based standards. Currently, the quality and type of treatment a patient receives can depend heavily on their "postal code." The REAL Alliance—a coalition of clinical and academic leaders—has developed a made-in-Canada framework to ensure equitable, timely, and consistent treatment across all provinces and territories.
2. Regulatory Modernization and Precision Oncology
The second recommendation urges the federal government to invest in reducing "red tape" and regulatory barriers that delay the introduction of innovative diagnostics and treatments. BCC emphasizes the need for precision oncology infrastructure—treatment tailored to the genetic profile of the individual—and equitable access to biomarker testing. The submission highlights that delays in drug approval and provincial funding directly correlate to life-years lost.
3. Funding for AI-Driven Patient Outcomes (PROgress Tracker)
BCC is requesting $850,000 in federal funding to expand the "PROgress Tracker," the only country-wide longitudinal study of patient-reported outcomes in Canada. Utilizing AI to enhance data reliability, this study tracks the patient journey over a 10-year period. The funding would support database management at the University of Calgary, ethics oversight, and clinician training to ensure that real-world evidence informs future health system planning.
Chronology: From Advocacy to Federal Consultation
The journey toward this budget submission began in 1991, when Breast Cancer Canada (formerly the Breast Cancer Society of Canada) was established with a singular focus on research. Over the last 30 years, the organization has evolved from a fundraising body into a primary driver of policy change.
The development of the REAL Canadian Breast Cancer Alliance (REAL standing for Research, Evidence, Access, and Learning) was a pivotal milestone in this timeline. Recognizing that provincial variations in chemotherapy and surgical norms were leading to unequal outcomes, BCC convened the Alliance to create a unified clinical consensus.
In recent years, the rise of precision medicine and AI prompted the launch of the PROgress Tracker. This shift moved the focus from general statistics to "real-world evidence," capturing the nuanced experiences of survivors. The current submission to the Pre-Budget Consultations in Advance of the Upcoming Federal Budget represents the culmination of these efforts, positioning BCC as a critical stakeholder in the federal government’s health policy deliberations for 2025 and beyond.
Supporting Data: The Stagnant Reality of Breast Cancer in Canada
Despite significant technological leaps in other areas of medicine, the statistical reality of breast cancer in Canada remains sobering. The BCC submission provides data that underscores the necessity of their recommendations:
- The Incidence Rate: One in eight Canadian women will be diagnosed with breast cancer in their lifetime. It remains the most common cancer among women, accounting for 25% of all new cancer cases.
- The Mortality Gap: While early detection has improved, breast cancer still accounts for 14% of all cancer deaths in women. The annual death toll of 5,500 has not seen a substantial decline in 20 years, suggesting that current treatment delivery systems have reached a plateau.
- The Financial Toxicity: New data from the PROgress Tracker reveals a hidden crisis of "financial toxicity." Approximately 69% of Canadians report that a diagnosis would severely jeopardize their financial stability. This is particularly acute for patients under the age of 55, who are often in their peak earning years and may lack the insurance coverage or savings to manage the hidden costs of care.
- Regional Inconsistency: Documented variations in chemotherapy use across British Columbia, Manitoba, Ontario, and Nova Scotia suggest that local practice norms, rather than patient needs or the latest science, often dictate care.
Official Responses: Expert and Advocacy Perspectives
The recommendations have garnered significant support from the medical and advocacy communities. Leaders within the REAL Canadian Breast Cancer Alliance argue that the Public Health Agency of Canada (PHAC) has a clear precedent for adopting such guidelines.
"PHAC has historically adopted expert advisory recommendations for conditions like Lyme disease and various physical activity benchmarks," the submission notes. "Adopting the REAL Alliance standards is a natural extension of this role."
Advocates emphasize that the 95% of Canadians who believe public healthcare policy should be influenced by industry experts are waiting for the government to act. Kimberly Carson, CEO of Breast Cancer Canada, has frequently stated that the goal is to move beyond "one-size-fits-all" medicine. The organization argues that by supporting the PROgress Tracker, the government is investing in a tool that allows clinicians to identify gaps in survivorship care that are currently invisible to the traditional healthcare system.
Furthermore, the push for regulatory modernization aligns with international efforts like Project Orbis. This initiative, led by the U.S. FDA in collaboration with Health Canada, aims to provide concurrent submission and review of oncology products. However, BCC points out that while Project Orbis is a vital step, the internal "red tape" within the Canadian market remains a deterrent for global innovators.
Implications: Economic Stability and the Future of Precision Care
The implications of the federal government’s response to this submission extend far beyond the clinical setting. BCC’s proposal frames breast cancer care as an economic imperative.
Economic Participation
By accelerating access to innovative treatments, the government can reduce "life years lost" and enable survivors to return to work. In a period of labor shortages and economic volatility, maintaining the workforce participation of the thousands of women diagnosed each year is a significant macro-economic benefit.
Healthcare Sustainability
The implementation of national standards and the use of AI-driven data (PROgress Tracker) would lead to more optimized resource use. By identifying which treatments work best for specific genetic profiles, the healthcare system can avoid the costs associated with ineffective "trial-and-error" therapies. Precision oncology is not just about better care; it is about a more sustainable and cost-effective health system.
Global Leadership
If the federal government adopts these recommendations, Canada could emerge as a global leader in breast cancer research and diagnosis. The integration of AI in structured pathology reports and the use of real-world evidence to inform policy would set a benchmark for other nations grappling with aging populations and rising cancer rates.
Conclusion
Breast Cancer Canada’s submission to the federal government is more than a request for funding; it is a blueprint for a systemic overhaul. As the 2025 budget process moves forward, the focus will remain on whether the government is willing to provide the $850,000 for data infrastructure and the political will to dismantle the regulatory barriers that currently stand between patients and life-saving innovation.
"By acting now," the submission concludes, "we can ensure that no one faces this disease without the support and resources they need to not only survive, but thrive."
About the Author
